

# Are Autoimmune Thyroid Dysfunction and Depression Related?\*

VICTOR J. POP, LUC H. MAARTENS, GERALINE LEUSINK, MAARTEN J. VAN SON, ANDRE A. KNOTTNERUS, ANTHONY M. WARD, RUSSELL METCALFE, AND ANTHONY P. WEETMAN

*Department of Social and Behavioral Sciences, University of Tilburg (V.J.P.); Diagnostic Center Eindhoven (L.H.M., G.L.), Eindhoven; the Department of Clinical and Health Psychology, University of Utrecht (M.J.v.S.), Utrecht; and the Department of Family Medicine, University of Maastricht (A.A.K.), Maastricht, The Netherlands; the Departments of Immunology (A.M.W.) and Medicine (R.M., A.P.W.), University of Sheffield, Sheffield, United Kingdom S5-7AU*

## ABSTRACT

The objective of this study was to examine the relationship between autoimmune thyroid disease and depression in perimenopausal women. Thyroid function [TSH, free T<sub>4</sub>, and thyroid peroxidase antibodies (TPO-Ab)] and depression (using the Edinburgh Depression Scale) were assessed cross-sectionally together with other determinants of depression. The subjects were 583 randomly selected perimenopausal women (aged 47–54 yr) from a community cohort of 6846 women. The main outcome measures were the occurrence of thyroid dysfunction (abnormal free T<sub>4</sub> and/or TSH or elevated levels of TPO-Ab) and the concomitant presence of depression according to the

Edinburgh Depression Scale. Neither biochemical thyroid dysfunction nor menopausal status was related to depression. Apart from several psycho-social determinants (the occurrence of a major life event, a previous episode of depression, or financial problems), an elevated level of TPO-Ab ( $\geq 100$  U/mL) was significantly associated with depression (odds ratio, 3.0, 95% confidence interval, 1.3–6.8). We conclude that women with elevated TPO-Ab levels are especially vulnerable to depression, whereas postmenopausal status does not increase the risk of depression. (*J Clin Endocrinol Metab* 83: 3194–3197, 1998)

SEVERAL clinical signs and symptoms of thyroid dysfunction are similar to depression, and depression may be provoked by underlying overt hypothyroidism (1–3). T<sub>4</sub> replacement increases central 5-hydroxytryptamine activity and reduces depressive symptoms (4). Depressed in-patients have an increased incidence of (sub)clinical thyroid dysfunction, and women suffering from postpartum depression have a higher prevalence rate of elevated thyroid peroxidase antibody (TPO-Ab) levels, an important marker of autoimmune thyroid disease (5–8). Moreover, the occurrence of stressful life events (an important determinant of depression) is a risk factor for the development of thyroid dysfunction, particularly Graves' disease (9, 10). Most, if not all, of these studies have reported a correlation while only (and often retrospectively) investigating an association at an univariate level. However, the origin of depression is multifactorial, which means that when looking at the effect of one variable on depression, the influence of other determinants of depression should simultaneously be taken into account (11). One explanation of the suggested relationship between stress and thyroid disease could be that stress causes depression, which, in turn, causes or exacerbates autoimmune thyroid disease.

We have investigated cross-sectionally the relationship

between thyroid dysfunction and depression in a community cohort of perimenopausal women in whom, apart from thyroid function, several determinants related to depression were assessed.

## Subjects and Methods

### Subjects and sample size

Between September 1994 and September 1995, all women between 47–54 yr of age (n = 8503) living in the city of Eindhoven in the southeast Netherlands were invited for screening of bone mineral density (BMD). Screening occurred at the Diagnostic Center (Eindhoven, The Netherlands) and at the St. Joseph Hospital (Veldhoven, The Netherlands), a suburb of Eindhoven. During the visit for BMD screening, detailed menstrual, gynecological, and general medical histories as well as the use of medication were determined by paramedical assistants. Blood samples were collected and stored. The women were asked to complete several questionnaires at home and to return these within 1 week of screening. For methodological reasons (use of self-rating scales, racial aspects related to osteoporosis), only Dutch Caucasian women [n = 8098, of whom 6648 (78%) participated in the study] were included in the analysis; 6116 (92%) of these women returned the questionnaires, of whom 4975 (81%) correctly completed the self-rating scales. A 1 in 2 random sample was selected for the assessment of thyroid status (n = 2584). Assuming a prevalence of depression of 25% and of elevated TPO-Ab titers of 10% (type I error ( $\alpha$ ) of 0.05 and a power of 0.80), a minimum of 548 women would be needed to detect a relative risk of at least 2.0 for TPO-Ab in relation to depression. Therefore, from these 2584 women, a 1 in 4 random sample was drawn, resulting in 583 women in whom thyroid status, depression, and determinants of depression were assessed.

As well as the subject's own informed consent, permission for the study was obtained from the medical ethics committee at the St. Joseph Hospital (Veldhoven, The Netherlands).

Received March 18, 1998. Revision received May 28, 1998. Accepted June 16, 1998.

Address all correspondence and requests for reprints to: Victor J. Pop, M.D., Ph.D., Department of Social and Behavioral Science, University of Tilburg, P.O. Box 90153, 5000 LE Tilburg, The Netherlands.

\* This work was supported by a grant from the Praeventiefonds (Project 002824010), the Dr. De Grood Foundation, and Merck Pharmaceuticals (Amsterdam, The Netherlands).

**TABLE 1.** Characteristics of the samples of Dutch Caucasian perimenopausal women (47–54 yr)

|   | A          | B          | C          |
|---|------------|------------|------------|
| No. of women                                    | 4975       | 2584       | 583        |
| Mean age (yr) of women (SD)                     | 50.0 (2.1) | 50.2 (1.9) | 49.9 (2.2) |
| Educational level [no. (%)]                     |            |            |            |
| Primary school                                  | 648 (13)   | 311 (12)   | 58 (10)    |
| Secondary school                                | 1890 (38)  | 904 (35)   | 216 (37)   |
| Low college degree                              | 1844 (37)  | 1111 (43)  | 239 (41)   |
| High college degree                             | 498 (10)   | 206 (8)    | 52 (9)     |
| Academic degree                                 | 99 (2)     | 52 (2)     | 17 (3)     |
| Gynecological status [no. (%)]                  |            |            |            |
| Women on hormone replacement therapy (HRT)      | 1194 (24)  | 568 (22)   | 151 (26)   |
| Menstruation pattern in women not receiving HRT |            |            |            |
| Premenopausal                                   | 646 (13)   | 362 (14)   | 70 (12)    |
| Perimenopausal                                  | 1492 (30)  | 723 (28)   | 181 (31)   |
| Postmenopausal                                  | 1044 (21)  | 594 (23)   | 128 (22)   |
| Women with hysterectomy                         | 945 (19)   | 439 (17)   | 116 (20)   |
| Women with oophorectomy                         | 398 (8)    | 155 (6)    | 41 (7)     |
| Parity  |            |            |            |
| No pregnancy                                    | 547 (11)   | 232 (9)    | 70 (12)    |
| Primipara                                       | 796 (16)   | 490 (19)   | 99 (17)    |
| Multipara                                       | 3632 (73)  | 1921 (74)  | 414 (71)   |
| Lifestyle habits [no. (%)]                      |            |            |            |
| Currently smoking                               | 1890 (38)  | 878 (34)   | 210 (36)   |
| Regular alcohol intake                          | 2537 (51)  | 1266 (49)  | 280 (48)   |
| Thyroid parameters [no. (%)]                    |            |            |            |
| Clinical hyperthyroidism                        |            | 16 (0.6)   | 3 (0.5)    |
| Clinical hypothyroidism                         |            | 13 (0.5)   | 2 (0.4)    |
| Subclinical hyperthyroidism                     |            | 54 (2.1)   | 15 (2.5)   |
| Subclinical hypothyroidism                      |            | 98 (3.8)   | 23 (4)     |
| TPO-Ab ≥100 U/mL                                |            | 245 (9.5)  | 58 (10)    |
| Euthyroidism on drug therapy                    |            | 23 (0.9)   | 6 (1)      |
| Previous treatment of hyperthyroidism           |            | 62 (2.4)   | 13 (2.2)   |
| EDS scores (mean, SD)                           | 7.3 (5.9)  | 7.1 (6.1)  | 7.2 (6.2)  |
| Depression (≥12 on EDS)                         | 1194 (24)  | 543 (21)   | 134 (23)   |

A, Characteristics of the women who completed all screening questionnaires (n = 4975); B, characteristics of randomly selected women in whom thyroid parameters were assessed (n = 2584); C, characteristics of the women in whom thyroid function and depression parameters were assessed (n = 583).

**Measurements**

**Depression.** Depression was assessed using the Edinburgh Depression Scale, originally called the Edinburgh Postnatal Depression Scale, which is a 10-item self-rating scale; the reliability, sensitivity, and specificity of this scale for detecting depression have been proven in postpartum women (12–14). Recently, the Edinburgh Postnatal Depression Scale has been validated for use in nonchild-bearing women and has shown accurate psychometric characteristics resulting in another nomenclature: the Edinburgh Depression Scale (EDS) (15). A score of 12 or higher on the EDS was defined as depression. Because this study was part of a larger longitudinal study program of depression in perimenopausal women, after screening, a subgroup of 320 women was subsequently visited at home, and a syndromal diagnosis of depression was made during an interview using the Research Diagnostic Criteria (16). Again, the EDS was completed and showed appropriate psychometric characteristics: a predictive value, sensitivity, and specificity for detecting (syndromal) depression of 71%, 68%, and 92%, respectively.

**Thyroid function.** Thyroid function was assessed by the measurement of free T<sub>4</sub> (fT<sub>4</sub>; reference range, 8–26 pmol/L; Abbott, North Chicago, IL), TSH (reference range, 0.4–6 mU/L; Abbott), and TPO-Ab (Autozyme Tab, Cambridge Life Sciences, Cambridge, UK). The coefficients of variation for fT<sub>4</sub> were 6.8%, 8.2%, and 6.7% at concentrations of 6.4, 18, and 30 pmol/L, respectively; those for TSH were 9.8%, 4.8%, 3.9%, and 3.1% at concentrations of 0.06, 0.75, 6.8, and 30 mU/L, respectively; and that for TPO-Ab was 9.6% at a concentration of 231 U/mL. Moreover, personal and family histories of (previous) thyroid dysfunction were assessed during the screening for BMD. Clinical thyroid dysfunction was defined by the presence of both abnormal TSH and fT<sub>4</sub> concentrations, whereas subclinical thyroid dysfunction was defined by abnormal TSH

concentrations with normal fT<sub>4</sub> levels. A TPO-Ab level of 100 U/mL or higher was defined as positive.

**Determinants of depression.** The determinants of depression, assessed in the group of 583 women who completed the EDS and in whom thyroid function was evaluated, included educational level, previous history of depression in the woman herself or in her first degree relatives, life-style habits (current smoking and alcohol intake), marital state, working outside the home, financial problems, and the occurrence of a major life event (11). Data analysis refers to this cohort of 583 women.

**Statistical analysis**

Statistical analysis was performed using the Statistical Products and Service Solutions (SPSS, Evanston, IL). The relationship between thyroid dysfunction and depression was investigated by multiple logistic regression analysis, with a high score on the EDS (≥12) as the dependent variable.

**Results**

The characteristics of the women in the various cohorts are shown in Table 1. The demographic features, gynecological status, life-style habits, and thyroid parameters were equally distributed in the total cohort (n = 4975), in the cohort of women in whom thyroid function was assessed (n = 2584), and in the cohort of women (n = 583) in whom the questions being studied were analyzed.

According to the EDS (≥12), the prevalence of depression

was equally distributed in the three cohorts (24%, 21%, and 23%, respectively; Table 1). Subset analysis in pre-, peri-, and postmenopausal women did not reveal any difference in prevalence rates of TPO-Ab and depression.

Of the 583 women in whom both thyroid function and determinants of depression were assessed, 3 (0.5%) had clinical hyperthyroidism, 2 (0.4%) had clinical hypothyroidism, 15 (2.5%) had subclinical hyperthyroidism, 23 (4%) had subclinical hypothyroidism, and 58 (10%) had high TPO-Ab levels ( $\geq 100$  U/mL). An additional 6 women (1%) were euthyroid due to thyroid hormone therapy, and 13 (2.2%) were euthyroid due to previous treatment for hyperthyroidism. Several independent thyroid-related and psycho-social variables were entered into a multiple logistic regression analysis, using a high score on the EDS ( $\geq 12$ ) as the dependent variable (Table 2). The occurrence of financial problems, caring for parents, a previous episode of depression in the woman's life, the occurrence of a major life event, and an elevated concentration of TPO-Ab ( $\geq 100$  U/mL) were all significantly and independently related to depression. Thyroid dysfunction (either clinical or subclinical) was not related to depression and neither was menopausal status.

### Discussion

The characteristics of the various study groups are similar, indicating that the group of women studied is representative of the total community-based cohort of perimenopausal women. Most studies investigating the relationship between menopausal state and depression failed to use a standardized assessment of depression or to show evidence that the study group was representative of the general population of perimenopausal women (17). In the present study, neither the presence of perimenopausal complaints nor the menopausal status of the women was related to depression, which suggests that changes in hormone concentrations of estrogens and progesterone (as reflected by an irregular menstruation

pattern) do not make a woman more susceptible to depressive symptoms (17). Postnatal women also failed to show a relationship between abrupt changes in estrogens and progestagens after child-bearing and the occurrence of depression (18).

Recent epidemiological studies on the occurrence of depression in the general population revealed a 1-yr (period) prevalence of 7–11% (19, 20). In postnatal women, a (period) prevalence of 10–15% has been shown (18), and several studies of perimenopausal women have indicated a (period) prevalence in the community of 16–21% and even of 36% at perimenopausal clinic (19–21). Apparently, although our study did not show any correlation between perimenopausal status and depression, women of this age seem to be especially vulnerable to depression.

This is the first study to show that women with a high concentration of TPO-Ab are at risk for depression (odds ratio, 3.0; 95% confidence interval, 1.3–6.8), a relationship that still exists after adjustment for other (psycho-social) determinants of depression. There are several postpartum studies and studies of a general psychiatric population that also report a correlation between depression or a rapid cycling mood disorder and TPO-Ab status (although at an univariate level), whereas others failed to find a relationship (7, 8, 22, 23). Because there is general agreement that the origin of depression is multifactorial, possible biological explanations of depression should be studied together with the influence of other psychological aspects, such as educational level, socio-economic status, the occurrence of major life events, and a family history of depression (11).

Up to 10% of fertile women have elevated levels of TPO-Ab, and once an individual is TPO-Ab positive, he or she will tend to remain so for the rest of his/her life and will be at high risk of developing clinical thyroid dysfunction in the future (3, 24). Recommendations have been made for screening women during or after pregnancy to detect TPO-Ab-positive cases, who are at risk of developing thyroid dysfunction during pregnancy, postpartum, or later in life (25). This study would add another argument for screening for TPO-Ab during pregnancy, because of the significant association with later depression.

The cross-sectional design of our study does not resolve the problem of whether autoimmune thyroid dysfunction (as reflected by the presence of TPO-Ab) precedes depression or *vice versa*. The only way to address this would be to undertake a longitudinal study, during which subjects would be followed for a long period of time. Pregnant women would be an appropriate study population; 10% have elevated levels of TPO-Ab (and remain positive for the rest of their lives), and the prevalence of depression is high, with a lifelong cumulative incidence of depression of at least 20% (18–20).

We conclude that depression, although not related to menopausal status, has a high prevalence in perimenopausal women in the community. The psycho-social determinants of depression are no different from those found for depression in general. The presence of one biological stable marker (TPO-Ab) is associated with and may make women more vulnerable for depression.

**TABLE 2.** Multiple logistic regression analysis (n = 583), with depression (score  $\geq 12$  on the EDS) as the dependent variable

| Variable                       | O.R. | 95% CI   |
|--------------------------------|------|----------|
| <b>Psycho-social factors</b>   |      |          |
| High educational level         | 1.9  | 0.5–5.9  |
| Marital state                  | 1.3  | 0.4–5.4  |
| Previous episode of depression | 4.8  | 2.3–6.9  |
| Depression in family           | 3.1  | 0.8–7.8  |
| Occurrence of major life event | 2.1  | 1.2–4.6  |
| Financial problems             | 3.3  | 1.8–6.2  |
| Caring for parents             | 2.7  | 1.5–4.8  |
| Working outside home           | 1.9  | 1.3–3.8  |
| <b>Gynecological state</b>     |      |          |
| Regular menstruation pattern   | 1.4  | 0.5–6.2  |
| Multiparity                    | 1.7  | 0.6–4.2  |
| Hot flushes                    | 1.5  | 0.4–4.1  |
| Sweating at night              | 1.3  | 0.6–4.2  |
| Hormonal substitution          | 1.4  | 0.8–1.5  |
| Uterus extirpation             | 1.6  | 0.7–2.1  |
| <b>Thyroid parameters</b>      |      |          |
| Clinical hyperthyroidism       | 6.1  | 0.6–19.8 |
| Clinical hypothyroidism        | 7.9  | 0.8–16.4 |
| Subclinical hyperthyroidism    | 3.3  | 0.7–10.5 |
| Subclinical hypothyroidism     | 2.9  | 0.9–8.9  |
| TPO-Ab titer $\geq 100$ U/mL   | 3.0  | 1.3–6.8  |

**Acknowledgments**

The authors thank the members of the Eindhoven Study management team, Dr. J. Keyzer, Prof. Dr. H. Pols, and Prof. Dr. S. Papapoulos, for their participation in the study and their critical review of the manuscript.

**References**

1. **Lazarus JH.** 1997 Hyperthyroidism. *Lancet.* 349:339–343.
2. **Lindsay RS, Toft AD.** 1997 Hypothyroidism. *Lancet.* 349:413–417.
3. **Weetman AP.** 1997 Hypothyroidism: screening and subclinical disease. *Br Med J.* 314:1175–1178.
4. **Cleare AJ, McGregor A, Chambers SM, Dawling S, O’Keane V.** 1996 Thyroxine replacement increases central 5-hydroxytryptamine activity and reduces depressive symptoms in hypothyroidism. *Neuroendocrinology.* 64:65–69.
5. **Esposito S, Prange AJ, Golden RN.** 1997 The thyroid axis, and mood disorders: overview and future perspectives. *Psychopharmacol Bull.* 33:205–217.
6. **Pop VJ, de Rooy HA, Vader HL, et al.** 1991 Postpartum thyroid dysfunction and depression in an unselected population. *N Engl J Med.* 324:1815–1816.
7. **Harris B, Othman S, Davies JA, et al.** 1992 Association between postpartum thyroid dysfunction and thyroid antibodies and depression. *Br Med J.* 305:152–156.
8. **Pop VJ, de Rooy HA, Vader HL, Heide van der D, van Son MJ, Komproe I.** 1993 Microsomal antibodies during gestation in relation to postpartum thyroid dysfunction and depression. *Acta Endocrinol Scand.* 129:26–30.
9. **Winsa B, Adami HO, Bergstrom R, et al.** 1991 Stressful life events and Graves’ disease. *Lancet.* 338:1475–1479.
10. **Kung AW.** 1995 Life events, daily stresses, and coping in patients with Graves’ disease. *Clin Endocrinol (Oxf).* 42:303–308.
11. **Gelder M, Gath D.** 1994 Affective disorders. In: Gelder M, Gath D, Mayou R, eds. *Oxford textbook of psychiatry.* Oxford: Oxford Medical Publications. 133–162.
12. **Cox JL, Holden JM, Sagovsky R.** 1987 Detection of depression: development of the 10-item Edinburgh Postnatal Depression Scale. *Br J Psychiatry.* 150:782–786.
13. **Harris B, Huckle P, Thomas R, John S, Fung H.** 1989 The use of rating scales to identify postnatal depression. *Br J Psychiatry.* 154:813–817.
14. **Pop VJ, Komproe I, Son van MJ.** 1992 Characteristics of the Edinburgh Postnatal Depression Scale in the Netherlands. *J Affect Disord.* 26:105–110.
15. **Cox JL, Chapman G, Murray D, Jones P.** 1996 Validation of the Edinburgh postnatal depression scale (EPDS) in non-postnatal women. *J Affect Disord.* 39:185–189.
16. **Spitzer RL, Endicott J.** 1975 Clinical criteria for psychiatric diagnosis and DSM-III. *Am J Psychiat.* 132: 773–782.
17. **Nicol-Smith L.** 1996 Causality, menopause, and depression: a critical review of the literature. *Br Med J.* 313:1229–1232.
18. **O’Hara MW.** 1995 Postpartum depression. Causes and consequences. New York: Springer Verlag.
19. **Kessler RC, McGonagle KA, Zhao S, et al.** 1994 Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Study. *Arch Gen Psychiatry.* 51:8–19.
20. **Bijl RV, Zessen van G, Ravelli A.** 1997 Psychiatric morbidity among adults in The Netherlands: the NEMESIS study II. Prevalence of psychiatric disorders. *Ned Tijdschr Geneesk.* 141:2453–2460.
21. **Hay AG, Bancroft J, Johnstone EC.** 1994 Affective symptoms in women attending a menopause clinic. *Br J Psychiatry.* 164:513–516.
22. **Oomen HA, Schipperijn AM, Drexhage HA.** 1996 The prevalence of affective disorder, and in particular rapid cycling of bipolar disorder in patients with abnormal thyroid function tests. *Clin Endocrinol (Oxf).* 45:215–223.
23. **Haggerty Jr JJ, Silva SG, Marquardt M, et al.** 1997 Prevalence of antithyroid antibodies in mood disorders. *Depress-Anxiety.* 5:91–96.
24. **Vanderpump MP, Tunbridge WM, French JM, et al.** 1995 The incidence of thyroid disorders in the community: a twenty-year follow-up of the Wickham Survey. *Clin Endocrinol (Oxf).* 43:55–68.
25. **Glinoe D.** 1997 The regulation of thyroid function in pregnancy: pathways of endocrine adaptation from physiology to pathology. *Endocr Rev.* 18: 404–425.

---

**9th European Congress on Obesity  
Universita degli Studi  
Milan, Italy  
June 3–6, 1999**

Executive Committee: Michele O. Carruba  
(E-mail: carruba@unimi.it)  
Franco Cavagnini  
(E-mail: cavagnini@auxologico.it)

For further information, please contact the Organizing Secretariat at:  
StudioGi  
Via Monte Rosa 14  
20149 Milano, Italy  
(E-mail: studiogi@tin.it)

The website address for the Congress is: [www.sameint.it/eco](http://www.sameint.it/eco)